Showing 7071-7080 of 7424 results for "".
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- Positive Findings Published for Provectus Pharmaceuticals' PV-10https://practicaldermatology.com/news/20130726-positive_findings_published_for_provectus_pharmaceuticals_pv-10/2459491/Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication,
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP P
- Leading Scientist Behind SkinCeuticals Dies At 76https://practicaldermatology.com/news/20130712-dr_sheldon_pinnell_the_founding_father_of_topical_antioxidants_leading_scientist_behind_skinceuticals_and_chief_emeritus_of_the_division_of_dermatolog/2459500/Dr. Sheldon Pinnell, an internationally eminent scientist, dermatologist, leading scientist behind L'Oreal-owned SkinCeuticals, and J. Lamar Callaway Professor Emeritus of Dermatology and Chief Emeritus of the Division of Dermatology at Duke University, passed away peacefully in Durham, North Caroli
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- ExtendCredit Launches “Cosmetic Credit Plans”https://practicaldermatology.com/news/20130702-extendcredit_launches_cosmetic_credit_plans/2459505/“Cosmetic Credit Plans” is a fully automated, customizable in-house financing software solution created specifically for the cosmetic surgery industry, offered by ExtendCredit. The software enables cosmetic surgeons to offer their own financi
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu
- Promising Data Presented for Viviscal Oral Supplement to Promote Hair Growthhttps://practicaldermatology.com/news/20130625-promising_data_presented_for_viviscal_oral_supplement_to_promote_hair_growth/2459510/An office-dispensed oral food supplement appears to promote existing hair growth for women suffering from temporary thinning hair, according to data presented at the World Hair Congress in Edinburgh, Scotland this spring. Subjects treated with Viviscal Hair Nourishment System
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials